FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 66 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q4 2019. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $1,596,000 | +27.7% | 525,000 | 0.0% | 0.08% | +55.8% |
| Q2 2019 | $1,250,000 | +11.1% | 525,000 | +75.0% | 0.05% | +26.8% |
| Q1 2019 | $1,125,000 | +4.5% | 300,000 | 0.0% | 0.04% | -44.6% |
| Q4 2018 | $1,077,000 | +870.3% | 300,000 | +1257.5% | 0.07% | +825.0% |
| Q2 2018 | $111,000 | -96.7% | 22,100 | -96.7% | 0.01% | -98.5% |
| Q1 2017 | $3,324,000 | – | 670,400 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DSC Advisors, L.P. | 1,667,377 | $15,440,000 | 9.38% |
| GREAT POINT PARTNERS LLC | 2,769,425 | $25,645,000 | 6.54% |
| Opaleye Management Inc. | 630,000 | $5,834,000 | 3.05% |
| Vivo Capital, LLC | 855,000 | $7,917,000 | 2.47% |
| DAFNA Capital Management LLC | 278,067 | $2,575,000 | 1.79% |
| RA Capital Management | 1,820,138 | $16,854,000 | 1.74% |
| SENZAR ASSET MANAGEMENT, LLC | 523,397 | $4,846,656,000 | 1.25% |
| Perceptive Advisors | 1,373,284 | $12,717,000 | 0.82% |
| Monashee Investment Management LLC | 225,000 | $2,084,000 | 0.73% |
| NEXTHERA CAPITAL LP | 125,000 | $1,158,000 | 0.71% |